Effect of progestin-based contraceptives on HIV-associated vaginal immune biomarkers and microbiome in adolescent girls.
Effect of progestin-based contraceptives on HIV-associated vaginal immune biomarkers and microbiome in adolescent girls.
- 2024
Available online through MWHC library: 2006 - present
Adolescent girls bear a disproportionate burden of both the HIV epidemic and unintended pregnancies; yet important questions remain unanswered regarding the effects of hormonal contraceptives on the vaginal immune microenvironment, which can impact HIV susceptibility in this group. Multiple studies report genital immune alterations associated with the progestin-based contraceptive Depot medroxyprogesterone acetate (DMPA) in adult women, but there is little available data in adolescents. The objective of this longitudinal cohort study was to evaluate the effects of short-term use of three progestin-based contraceptives, levonorgestrel intrauterine device (LNG-IUD), subdermal etonogestrel (ETNG), and injectable DMPA, on HIV-associated vaginal immune biomarkers and microbiome in adolescent girls. Fifty-nine sexually active, HIV-uninfected girls aged 15-19, were recruited from the Washington DC metro area and self-selected into Control (condoms only), combined oral contraceptive pills, LNG-IUD, ETNG and DMPA groups. Vaginal swabs were collected at baseline prior to contraceptive use and at 3-month follow-up visit. Vaginal secretions were tested for pro-inflammatory (IL-1alpha, IL-1beta, TNF-alpha, IL-6, IL-8, MIP-3alpha, IP-10, RANTES, MIP-1alpha, MIP-1beta) and anti-inflammatory/anti-HIV (Serpin-A1, Elafin, Beta-Defensin-2, SLPI) immune biomarkers using ELISA and for anti-HIV activity using TZM-bl assay. Vaginal microbiome was evaluated using 16S rRNA gene sequencing. Data were analyzed using SAS Version 9. Among the 34 participants who completed both visits, no significant changes in median biomarker concentrations, HIV inhibition and microbiome composition were observed between baseline and follow-up visits for any of the contraceptive groups. IL-8 (p<0.01), MIP-3alpha (0.02), Elafin (p = 0.03) and RANTES (p<0.01) differed significantly by race whereas IL-6 was significantly different by age (p = 0.03). We conclude that 3-month use of LNG-IUD, ETNG and DMPA have minimal effects on adolescent vaginal immune microenvironment, and therefore unlikely to impact HIV risk. Future studies with larger sample size and longer follow-up are recommended to continue to evaluate effects of contraceptives on the lower genital tract immunity and susceptibility to sexually transmitted infections. Copyright: © 2024 Nasr et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
English
1932-6203
PMC11249223 [pmc] PONE-D-23-19489 [pii]
*Biomarkers
*Desogestrel
*HIV Infections
*Levonorgestrel
*Medroxyprogesterone Acetate
*Microbiota
*Vagina
Adolescent
Biomarkers/me [Metabolism]
Contraceptive Agents, Female/ad [Administration & Dosage]
Contraceptive Agents, Female/pd [Pharmacology]
Desogestrel/ad [Administration & Dosage]
Elafin
Female
HIV Infections/im [Immunology]
Humans
Levonorgestrel/ad [Administration & Dosage]
Levonorgestrel/pd [Pharmacology]
Longitudinal Studies
Medroxyprogesterone Acetate/ad [Administration & Dosage]
Medroxyprogesterone Acetate/ae [Adverse Effects]
Medroxyprogesterone Acetate/pd [Pharmacology]
Microbiota/de [Drug Effects]
Progestins/ad [Administration & Dosage]
Progestins/pd [Pharmacology]
Vagina/de [Drug Effects]
Vagina/im [Immunology]
Vagina/mi [Microbiology]
Young Adult--Automated
MedStar Health Research Institute
MedStar Washington Hospital Center
Obstetrics and Gynecology
Journal Article
Available online through MWHC library: 2006 - present
Adolescent girls bear a disproportionate burden of both the HIV epidemic and unintended pregnancies; yet important questions remain unanswered regarding the effects of hormonal contraceptives on the vaginal immune microenvironment, which can impact HIV susceptibility in this group. Multiple studies report genital immune alterations associated with the progestin-based contraceptive Depot medroxyprogesterone acetate (DMPA) in adult women, but there is little available data in adolescents. The objective of this longitudinal cohort study was to evaluate the effects of short-term use of three progestin-based contraceptives, levonorgestrel intrauterine device (LNG-IUD), subdermal etonogestrel (ETNG), and injectable DMPA, on HIV-associated vaginal immune biomarkers and microbiome in adolescent girls. Fifty-nine sexually active, HIV-uninfected girls aged 15-19, were recruited from the Washington DC metro area and self-selected into Control (condoms only), combined oral contraceptive pills, LNG-IUD, ETNG and DMPA groups. Vaginal swabs were collected at baseline prior to contraceptive use and at 3-month follow-up visit. Vaginal secretions were tested for pro-inflammatory (IL-1alpha, IL-1beta, TNF-alpha, IL-6, IL-8, MIP-3alpha, IP-10, RANTES, MIP-1alpha, MIP-1beta) and anti-inflammatory/anti-HIV (Serpin-A1, Elafin, Beta-Defensin-2, SLPI) immune biomarkers using ELISA and for anti-HIV activity using TZM-bl assay. Vaginal microbiome was evaluated using 16S rRNA gene sequencing. Data were analyzed using SAS Version 9. Among the 34 participants who completed both visits, no significant changes in median biomarker concentrations, HIV inhibition and microbiome composition were observed between baseline and follow-up visits for any of the contraceptive groups. IL-8 (p<0.01), MIP-3alpha (0.02), Elafin (p = 0.03) and RANTES (p<0.01) differed significantly by race whereas IL-6 was significantly different by age (p = 0.03). We conclude that 3-month use of LNG-IUD, ETNG and DMPA have minimal effects on adolescent vaginal immune microenvironment, and therefore unlikely to impact HIV risk. Future studies with larger sample size and longer follow-up are recommended to continue to evaluate effects of contraceptives on the lower genital tract immunity and susceptibility to sexually transmitted infections. Copyright: © 2024 Nasr et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
English
1932-6203
PMC11249223 [pmc] PONE-D-23-19489 [pii]
*Biomarkers
*Desogestrel
*HIV Infections
*Levonorgestrel
*Medroxyprogesterone Acetate
*Microbiota
*Vagina
Adolescent
Biomarkers/me [Metabolism]
Contraceptive Agents, Female/ad [Administration & Dosage]
Contraceptive Agents, Female/pd [Pharmacology]
Desogestrel/ad [Administration & Dosage]
Elafin
Female
HIV Infections/im [Immunology]
Humans
Levonorgestrel/ad [Administration & Dosage]
Levonorgestrel/pd [Pharmacology]
Longitudinal Studies
Medroxyprogesterone Acetate/ad [Administration & Dosage]
Medroxyprogesterone Acetate/ae [Adverse Effects]
Medroxyprogesterone Acetate/pd [Pharmacology]
Microbiota/de [Drug Effects]
Progestins/ad [Administration & Dosage]
Progestins/pd [Pharmacology]
Vagina/de [Drug Effects]
Vagina/im [Immunology]
Vagina/mi [Microbiology]
Young Adult--Automated
MedStar Health Research Institute
MedStar Washington Hospital Center
Obstetrics and Gynecology
Journal Article